Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Matthew Anson, Sizheng Steven Zhao, Philip Austin, et al.
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1869-1881
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Prevention of Cardiovascular Disease in Type 1 Diabetes
Camila Manrique‐Acevedo, Irl B. Hirsch, Robert H. Eckel
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1207-1217
Closed Access | Times Cited: 17
The Effect of Sodium–Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type 1 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled Trials
Paschalis Karakasis, Djordje S. Popovic, Dimitrios Patoulias, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 2, pp. 521-532
Open Access | Times Cited: 9
Use of Cardioprotective Adjuncts in Type 1 Diabetes
Jerry R. Greenfield, R. J. Frampton, Kellie Millard, et al.
Diabetes Therapy (2025)
Open Access | Times Cited: 1
Excessive Initial Renal Function Decline Following Sodium-Glucose Cotransporter-2 Inhibitor Treatment Predicts Major Adverse Cardiorenal Outcomes
Chi‐Yu Chen, Shao‐Sung Huang, Shuo-Ming Ou, et al.
Mayo Clinic Proceedings (2025)
Closed Access | Times Cited: 1
Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database
Matthew Anson, Alex E. Henney, Sizheng Steven Zhao, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2606-2623
Closed Access | Times Cited: 8
Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management
Aikaterini Eleftheriadou, Vincenza Spallone, Abd A. Tahrani, et al.
Diabetologia (2024) Vol. 67, Iss. 12, pp. 2611-2625
Open Access | Times Cited: 6
Canagliflozin Inhibits Hedgehog Interacting Protein (Hhip) Induction of Tubulopathy in Diabetic Akita Mice
Shiao‐Ying Chang, Min-Chun Liao, Kana N. Miyata, et al.
Translational research (2025) Vol. 277, pp. 13-26
Closed Access
Association of herpes zoster vaccination and cardiovascular risk in patients with diabetes: long-term insights from a retrospective cohort study
Edy Kornelius, Shih‐Chang Lo, Chien-Ning Huang, et al.
BMJ Open (2025) Vol. 15, Iss. 2, pp. e090428-e090428
Open Access
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Maria Apostolopoulou, Vaia Lambadiari, Michael Roden, et al.
Endocrine Reviews (2025)
Open Access
Four-year use of SGLT2i as adjunctive therapy in adults with type 1 diabetes: a real-world experience
Marina Valenzano, Louis Massari, Paolo Abrate, et al.
Acta Diabetologica (2025)
Closed Access
Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis
Anat Tsur, Avivit Cahn, Lior Hanoch, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Effect of dapagliflozin on blood and breath ketones during supervised insulin withdrawal in adults with type 1 diabetes: A randomized crossover trial
Max C. Petersen, Kai E. Jones, Alexander M. Markov, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Obesity and its management in primary care setting
Mahmoud Ibrahim, Ebtesam Ba-Essa, Jessica A. Alvarez, et al.
Journal of Diabetes and its Complications (2025) Vol. 39, Iss. 7, pp. 109045-109045
Closed Access
Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)
Pedro H. Reis‐Barbosa, Carlos Alberto Mandarim‐de‐Lacerda
Fundamental and Clinical Pharmacology (2024) Vol. 38, Iss. 6, pp. 1059-1068
Closed Access | Times Cited: 3
Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
Oscar Resnick, Fernando Bril, Giovanna Beauchamp
Frontiers in Endocrinology (2025) Vol. 15
Open Access
Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults
Marco Infante, F Silvestri, Nathalia Padilla, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1303-1303
Open Access
A comparison of ultra‐rapid and rapid insulin in automated insulin delivery for type 1 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Puguh Oktavian, Citrawati Dyah Kencono Wungu, Sony Wibisono, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks
Ahmad Mamoun Rajab, Sam M. Pearson, Ramzi Ajjan
Diabetes Obesity and Metabolism (2025)
Open Access
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on glycemic variability, islet cell function, and insulin resistance in patients with type 2 diabetes mellitus and renal cell carcinoma
Anqi Zhang, Xincheng Zhang, Aige Yang, et al.
American Journal of Cancer Research (2025) Vol. 15, Iss. 3, pp. 946-965
Closed Access
Updates in chronic kidney disease management: A systematic review
Amina Ammar, Stephanie B. Edwin, Rachel Whitney, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Open Access
Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis
Jie Ren, Shuhui Yang, Yifei Wang, et al.
British Journal of Clinical Pharmacology (2025)
Closed Access
Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study
Ayman Al Hayek, David C. Klonoff, Wael M. Al Zahrani, et al.
Journal of Diabetes and its Complications (2025) Vol. 39, Iss. 7, pp. 109064-109064
Closed Access
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Špela Volčanšek, Andrijana Koceva, Mojca Jensterle, et al.
Diabetes Therapy (2025)
Open Access
Long-term effects of adding an SGLT-2 inhibitor to insulin therapy in patients with type 1 diabetes. An observational study and systematic review of real-world evidence
Alberto Maran, Federico Boscari, Carlo Fagarazzi, et al.
Journal of Endocrinological Investigation (2025)
Open Access
Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
Djordje S. Popovic, Paschalis Karakasis, Theocharis Koufakis, et al.
Metabolism (2024) Vol. 153, pp. 155791-155791
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top